Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Phase II, Randomized, Placebo-controlled Trial in Patients With Charcot-marie-tooth Disease Type 1A

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Pharnext, SAS
ClinicalTrials.gov Identifier:
NCT01401257
First received: July 20, 2011
Last updated: September 11, 2013
Last verified: July 2011

July 20, 2011
September 11, 2013
December 2010
October 2011   (final data collection date for primary outcome measure)
Safety and tolerability of PXT3003 [ Time Frame: Screening, randomization, 1-, 3-, 6-, 9-, 12-month treatment and 1-month follow-up ] [ Designated as safety issue: Yes ]

The Primary Objective is to assess the clinical and laboratory safety and tolerability of three doses of PXT3003 administered orally for 12 months to CMT1A patients versus placebo.

Number of participants with adverse events in each arm.

Same as current
Complete list of historical versions of study NCT01401257 on ClinicalTrials.gov Archive Site
  • To obtain preliminary data on the efficacy of PXT3003 on clinical scores and functional tests [ Time Frame: Screening, randomization, 3-, 6-, 9- and 12-months treatment ] [ Designated as safety issue: No ]

    Efficacy scores and functional tests will be assessed CMTNS/CMTES:ONLS, VAS, fatigue, pain, six minute walk test (6MWT), nine-hole peg test, quantified muscular testing (QMT; hand grip and foot dorsiflexion), CGI.

    For each test or score, change from baseline after 3-,6-, 9- and 12-months of treatment.

  • To assess the pharmacodynamic effect of PXT3003 on PMP22 mRNA levels and intra-epidermal axon density in cutaneous biopsy [ Time Frame: Randomization and 12-month treatment ] [ Designated as safety issue: No ]

    A cutaneous biopsy (consisting in 2 small punch biopsies) will be performed to assess PMP22 mRNA expression and intra-epidermal axon density.

    Change from baseline after 12-month of treatment.

  • To assess the pharmacodynamic effect of PXT3003 on selected neurophysiological parameters [ Time Frame: Screening, randomization, 3-, 6-, 9- and 12-month treatment ] [ Designated as safety issue: No ]

    Electrophysiological examination will be performed to assess sensory and motor responses of the median and ulnar nerves (non-dominant side) including: NCV, compound muscle action potential (CMAP) and SNAP.

    Change from baseline after 3-,6-, 9- and 12-months of treatment.

  • To assess the pharmacodynamic effect of PXT3003 on a series of biochemical biomarkers [ Time Frame: Randomization and 3-month treatment ] [ Designated as safety issue: No ]

    Dosages of biochemical biomarkers in plasma.

    Change from baseline after 3-month of treatment.

  • To assess the plasma concentrations of PXT3003 [ Time Frame: Randomization, 1-, 6- and 12-month treatment ] [ Designated as safety issue: Yes ]
    PXT3003 plasmatic concentrations after one administration (randomization) and after 1-,6-and 12-months of treatment.
Same as current
Not Provided
Not Provided
 
Phase II, Randomized, Placebo-controlled Trial in Patients With Charcot-marie-tooth Disease Type 1A
A Phase II, Randomized, Placebo-controlled Trial of the Safety, Efficacy, Pharmacodynamics and Pharmacokinetics of PXT3003 in Patients With Charcot-Marie-Tooth Disease Type 1A.

The present trial is a randomized, placebo-controlled study evaluating 3 different doses of PXT3003 in patients with CMT1A disease.

In addition to the safety and tolerability of the treatment, clinical, electrophysiological and biological endpoints (PMP22 mRNA, skin biopsy histology and plasma biomarkers) will be assessed. Standard laboratory tests and drug plasma concentrations will also be measured. Because of the slow progression of the disease and the nature of the observed symptoms, a minimum duration of 12 months of treatment is required in order to observe a potential improvement in any of the efficacy parameters.

Interventional
Phase 2
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
  • Charcot-Marie-Tooth Disease
  • Hereditary Neuropathy With Liability to Pressure Palsies
  • Genetic Disorders
  • Tooth Disorders
  • Drug: PXT3003
    Liquid,5 ml, twice a day, 12-month treatment
    Other Name: Pleocompound PXT3003
  • Other: Placebo
    Liquid,5 ml, twice a day, 12-month treatment
    Other Name: Pleocompound PXT3003
  • Experimental: PXT3003 Low dose
    Oral Liquid formulation, 1/100, bid, 12 months
    Intervention: Drug: PXT3003
  • Experimental: PXT3003 Intermediate dose
    Oral Liquid formulation, 1/50, bid, 12 months
    Intervention: Drug: PXT3003
  • Experimental: PXT3003 High dose
    Oral Liquid formulation, 1/10, bid, 12 months
    Intervention: Drug: PXT3003
  • Placebo Comparator: Placebo
    Oral Liquid formulation, bid, 12 months
    Intervention: Other: Placebo
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
80
December 2012
October 2011   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • DNA proven CMT1A
  • Muscle weakness in at least foot dorsiflexion (clinical assessment)
  • Age between 18 and 65 years
  • Male or non pregnant, non breastfeeding female
  • CMT neuropathy score at screening ≤ 20
  • Agrees to perform electrorophysiological studies and two cutaneous biopsies for determination of PMP22 expression and histology
  • Providing signed written informed consent to participate in the study and willing and able to comply with all study procedures and scheduled visits

Exclusion Criteria:

  • Patients with another neurological disease
  • Patients using unauthorized concomitant treatments, ascorbic acid, opioids, levothyroxine and potentially neurotoxic drugs. Patients who can/agree to stop these medications 4 weeks before randomization can be included
  • Patients who have participated in another trial of investigational drug within the past 30 days
  • Concomitant major systemic disease
  • Clinically significant history of unstable medical illness over the last 30 days (unstable angina…)
  • History of significant hematologic, kidney, liver disease, or insulin-dependent diabetes
  • Clinically significant abnormalities on the prestudy laboratory evaluation, physical evaluation, electrocardiogram (ECG)
  • ASAT/ALAT levels above the upper limit of normal (ULN). However, patients with an isolated elevation of either ASAT or ALAT (<1.5 ULN) can be included at investigators‟ discretion if the remaining liver function tests are normal and if ASAT or ALAT value is stable at 2 distinct evaluations in the month prior to inclusion
  • Serum creatinine levels above the upper limit of normal
  • Limited mental capacity or psychiatric disease rendering the subject unable to provide written informed consent or comply with evaluation procedures
  • History of recent alcohol or drug abuse or non-adherence with treatment or other experimental protocols
  • Female of childbearing potential (apart of patient using adequate contraceptive measures), pregnant or breast feeding
  • Suspected inability to complete the study follow-up (foreign workers, transient visitors, tourists or any others for whom follow-up evaluation is not assured)
  • Limb surgery in the six months before randomization or planned before completion of the trial
  • Known hypersensitivity to any of the individual components of PXT3003
  • Porphyria
Both
18 Years to 65 Years
No
Contact information is only displayed when the study is recruiting subjects
France
 
NCT01401257
CLN-PXT3003-01
Yes
Pharnext, SAS
Pharnext, SAS
Not Provided
Principal Investigator: Shahram ATTARIAN, MD Hôpital La Timone
Study Director: Viviane BERTRAND, PhD Pharnext, SAS
Pharnext, SAS
July 2011

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP